Increased Vancomycin Clearance in Patients with Solid Malignancies-Reference-Cited by-同舟云学术

Increased Vancomycin Clearance in Patients with Solid Malignancies

Published:2020-07-01 Issue:7 Volume:43 Page:1081-1087
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Izumisawa Tomohiro¹²,Wakui Nobuyuki³,Kaneko Tomoyoshi²,Soma Masakazu²,Imai Masahiko¹,Saito Daisuke¹,Hasegawa Hideo²,Horino Tetsuya⁴,Takahashi Noriko¹

Affiliation:

1. Laboratory of Physiological Chemistry, Institute of Medicinal Chemistry, Hoshi University

2. Department of Laboratory Medicine, The Jikei University Kashiwa Hospital

3. Division of Applied Pharmaceutical Education and Research, Hoshi University

4. Department of Infectious Diseases and Infection Control, Jikei University School of Medicine

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/43/7/43_b20-00083/_pdf

Reference30 articles.

1. 1) Sakai C, Satoh Y, Ohkusu K, Kumagai K, Ishii A. Outbreak of methicillin-resistant Staphylococcus aureus (MRSA) infection or colonization among patients with neoplastic disease: a clinico-epidemiological study of 11 cases. Kansenshogaku Zasshi, 75, 940–945 (2001).

2. 2) van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob. Agents Chemother., 57, 734–744 (2013).

3. 3) Fujii S, Takahashi S, Makino S, Kunimoto Y, Nakata H, Noda N, Sakurai K, Miyamoto A. Impact of vancomycin or linezolid therapy on development of renal dysfunction and thrombocytopenia in Japanese patients. Chemotherapy, 59, 319–324 (2013).

4. 4) Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis., 52, e18–e55 (2011).

5. 5) Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, Grabsch EA, Roberts SA, Robson J, Read K, Bak N, Hurley J, Johnson PD, Morris AJ, Mayall BC, Grayson ML. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis., 38, 521–528 (2004).

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Brief Review of Pharmacokinetic Assessments of Vancomycin in Special Groups of Patients with Altered Pharmacokinetic Parameters;Current Drug Safety;2023-11

2. Altered Pharmacokinetics Parameters of Vancomycin in Patients with Hematological Malignancy with Febrile Neutropenia, a Bayesian Software Estimation;Antibiotics;2023-05-29

3. Effects of Antibacterial Agents on Cancerous Cell Proliferation;Biological and Pharmaceutical Bulletin;2023-05-01

4. Analysis of a machine learning–based risk stratification scheme for acute kidney injury in vancomycin;Frontiers in Pharmacology;2022-11-24

5. Prediction Accuracy of Area under the Concentration–Time Curve of Vancomycin by Bayesian Approach Using Creatinine-Based Equations of Estimated Kidney Function in Bedridden Elderly Japanese Patients;Biological and Pharmaceutical Bulletin;2022-06-01